Senior Medical Science Liaison

If you are unable to complete this application due to a disability, contact this employer to ask for an accommodation or an alternative application process.

Full Time Cambridge, Cambridge, MA, US

Salary Range: $ To $ Annually

Immuneering Corporation (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company developing oncology therapies using its proprietary Deep Cyclic Inhibition platform. Our lead asset, atebimetinib (IMM-1-104), is an oral, once-daily Deep Cyclic Inhibitor of MEK in active Phase 2 and Phase 3 (MAPKeeper 301) clinical trials in pancreatic cancer and RAS-mutant non-small cell lung cancer, as well as additional solid tumor programs. We are committed to delivering transformative treatments to patients with limited options through rigorous science and a collaborative, mission-driven culture.

This is a foundational hire. As Immuneering’s first US-based field medical employee, this role will establish the company’s scientific presence with key opinion leaders and academic oncology centers nationwide. This role is best suited for a senior MSL who is willing to engage with KOLs enthusiastically and build a rapport with the scientific community, with the strategic vision and potential to grow into a leadership position within a lean, mission-driven organization.

The selected MSL may have the opportunity to assist with the company’s international MSL buildout across Western Europe, Central-Eastern Europe, and the Australia/APAC region, and could quickly step into the role of Field Medical Director.

• Develop and manage peer-to-peer scientific relationships with oncology KOLs, academic investigators, and institutional stakeholders at priority centers including MSKCC, City of Hope, OHSU, and the SCRI/USON/One Oncology networks and others.
• As a major priority, this individual will support investigator identification and engagement for MAPKeeper 301 Phase 3 enrollment; facilitate site activation and scientific readiness at high-enrolling centers.
• Deliver accurate, balanced, and compliant scientific exchange on Immuneering’s Deep Cyclic Inhibition mechanism, MAPKeeper in metastatic pancreatic cancer, atebimetinib + cemiplimab in RAS-mutant NSCLC and other possible studies related to the MAPK pathway.
• Respond to unsolicited medical information requests from healthcare professionals in accordance with FDA guidelines on scientific exchange.
• Generate and communicate field insights — including HCP perspectives, competitive intelligence, and clinical practice patterns — to Medical Affairs, Clinical, and Commercial stakeholders.
• Provide flexible US territory coverage (East, Central/South, West) based on enrollment priorities and KOL geography.
• Represent Immuneering at national and regional oncology congresses (possibly including ASCO, AACR, ESMO and others).
• Partner with Medical Affairs leadership to develop scientific messaging frameworks, training curricula, and field activity standards for the global consultant network.
• May quickly transform into a leadership position as the Field Medical Director, which would entail managing the buildout of Immuneering’s OUS consultant MSL network across the UK/Western Europe, Central-Eastern Europe (Poland, Czech Republic, Hungary, Romania), and Australia/APAC.
• Contribute to MSL infrastructure, SOPs, and reporting frameworks as Immuneering scales toward commercialization or partnership.

• Advanced degree in a health science discipline (MD, PharmD, PhD, or MSN/NP/PA with oncology specialization)
• 3–5+ years of MSL experience in oncology; prior experience at a biotech or clinical-stage company strongly preferred

• Established KOL relationships in pancreatic cancer, thoracic oncology, or a closely adjacent tumor type
• Deep understanding of clinical trial design, oncology drug development, and FDA-compliant scientific exchange
• Ability to translate complex mechanistic science (RAS/MAPK pathway biology, adaptive resistance, combination strategies) for diverse oncology audiences
• Willingness and ability to travel 50–60% domestically; occasional international travel for global team alignment…